Recent Updates
Recently added Catalysts
SRPT Negative Sentiment Score: 25/100

Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SRPT

Key Takeaway: Sarepta Therapeutics, Inc. is facing a class action lawsuit filed by Levi & Korsinsky LLP, alleging securities law violations due to false statements regarding the safety of its gene therapy, ELEVIDYS. The suit claims that significant safety risks were not disclosed, and the trial protocols failed to identify severe side effects. As a result, Sarepta's recruitment and dosing in clinical trials could be halted, attracting regulatory scrutiny. Investors affected by these alleged violations are encouraged to contact the law firm before the deadline of August 25, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • Sarepta is facing a class action lawsuit over alleged securities fraud.
  • The lawsuit claims that Sarepta misled investors about the safety risks of its product, ELEVIDYS.
  • The complaint alleges major faults in the trial protocols and safety monitoring of ELEVIDYS.
  • Risk of halted recruitments and regulatory scrutiny could significantly impact Sarepta's drug approval process.

Full Press Release Details

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:
SRPT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.
WHAT'S NEXT? If you suffered a loss in Sarepta during the relevant time frame, you have until August 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the lawsuit against Sarepta Therapeutics about?

The lawsuit claims that Sarepta misled investors regarding safety risks related to its gene therapy, ELEVIDYS.

What period does the lawsuit cover for Sarepta investors?

The lawsuit addresses losses incurred by Sarepta investors between June 22, 2023, and June 24, 2025.

How can Sarepta investors join the class action?

Investors can request to join the class action until August 25, 2025, without any costs.

Who should Sarepta investors contact for more information?

Investors can contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call at (212) 363-7500.

Are there any fees to participate in the lawsuit?

No, class members may participate without any out-of-pocket costs or fees.

Last updated: Jul 8, 2025